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Multidisciplinary team (MDT) model in cancer care was introduced and endorsed to ensure that care delivery is consistent with
thebest available evidence. Over the last few years,regular MDTmeetings have become astandardpractice inoncology andgained
the status of the key decision-making forum for patient management. Despite the fact that cancer MDT meetings are well accepted
by clinicians, concerns are raised over the paucity of good-quality evidence on their overall impact. There are also concerns
over lack of the appropriate support for this important but overburdened decision-making platform. The growing acceptance
by clinical community of the health information technology in recent years has created new opportunities and possibilities of
using advanced clinical decision support (CDS) systems to realise full potential of cancer MDT meetings. In this paper, we present
targeted summary of the available evidence on the impact of cancer MDT meetings, discuss the reported challenges, and explore
the role that a CDS technology could play in addressing some of these challenges.
1. Background of MDT Meetings in
Cancer Management
Multidisciplinary team meetings are also known as tumour
boards, multidisciplinary cancer conferences, multidisci-
plinary case reviews, or multidisciplinary clinics, in diﬀerent
health care systems. These diﬀerent terms may represent
the variations in the organisational structure, membership,
approach,focus,andthedecisionprocessesofthesemeetings
[1]; however, they all provide a forum for multidisciplinary
cancer teams to regularly convene and discuss the diagnostic
and treatment aspects of patient care.
In MDT meetings the emphasis is on collaborative
decision-making and the treatment planning, where the core
team members of relevant specialties participate through the
MDT meetings to share their knowledge and make collective
evidence-based recommendations for patient management.
Theconceptofamultidisciplinaryforumtoshareknowledge
among clinicians from diﬀerent disciplines is not new
to oncology. Tumour boards have existed in the United
States for the last 50 years [2]. However, until recently,
their primary goal was educational rather than improving
patient care. In the 1980s a shift towards community-based
cancer care in the United States provided a stimulus to the
development of tumour boards, which facilitated sharing of
information amongst participating physicians with positive
beneﬁts for quality of care [3]. In the last two decades
there has been a transition of the primary goal of tumour
boards from education to the delivery of care. In the United
Kingdom, the overhaul of cancer services and subsequent
rapid adoption of MDMs in the last decade has been
primarily driven by political and public pressure resulting
from a series of reports published in the late 1990s which
highlighted wide variation in patients’ care [4]. Many other
European countries and Australia were quick to adopt the
M D Tm o d e lf o rc a n c e rc a r e[ 5, 6].
2.TheRationalebehindRegularMDTMeetings
In the United Kingdom, the National Health Service (NHS)
National Cancer Plan, published in 2000, endorsed the
multidisciplinary team model for the management of cancer2 International Journal of Breast Cancer
patients, and regular multidisciplinary team meetings have
since been endorsed as the means to achieve this. The
rationale for regular MDT meeting is multidimensional.
These forums aim to ensure that all patients receive
timely diagnosis and treatment, that patient management
is evidence-based, and that there is continuity of care. The
regular meetings facilitate information exchange and regular
communication ﬂow between all those involved in treatment
of the patient. The team members can monitor adherence to
evidence-based guidelines and can streamline the resources
for improved management strategies, lower waiting times
and enhanced cost eﬀectiveness. The MDT meeting provides
an opportunity for education and learning to its members
and trainee doctors. They may also improve the well-
being and work satisfaction of individual team members.
Cancer MDT meetings are also viewed as an important
opportunity to identify patients who are eligible for research
trials. It naturally follows that if the team functioning,
communication and decision-making are improved, then
ultimately both patient care quality and patient outcomes
will improve.
In the following section, we examine the empirical
evidence available in the literature to support the claimed
beneﬁts of cancer MDT meetings.
3. The Evidence on the Impact of
CancerMDT Meetings
We performed a detailed review of published evidence on the
eﬀectiveness of cancer MDT meetings. Table 1 summarises
the available evidence on the eﬀectiveness of cancer MDTs.
As depicted in this table, the published empirical evidence
to support the beneﬁts of cancer MDT meetings is weak
and limited. It is paradoxical that we expect our individual
clinical decisions to be based on sound empirical evidence
but not the same for organisational decisions.
3.1. Studies Showing No or Negative Impact. We identiﬁed
only one randomised controlled trial [7] that reported on
survival. The intervention arm of the trial consisted of a two-
stop centralised diagnostic pathway followed by MDT review
while the control arm was a conventional pathway without
MDT review. The patients recruited (N = 88) were those
with suspected lung cancer, who were considered ﬁt for a CT
scan and tissue biopsy. The study reported no statistically
signiﬁcant diﬀerence in the quality of life (QOL) at six
weeks and the survival at two years between intervention
and control arm. Two other observational studies evaluating
the role of MDT meetings in high-grade glioma [8]a n d
nonsmall cell lung cancer [9] also reported no statistically
signiﬁcant diﬀerence in survival between the MDT and
control groups.
The study [20] evaluated the inﬂuence of lung cancer
MDT meetings on the quality of decision-making and
reported that the change in net utility loss brought about
by multidisciplinary team discussion was not signiﬁcantly
diﬀerent from zero, and team discussion did not improve the
quality of decision-making overall.
3.2. Studies Showing Positive Impact. We identiﬁed eight
observational studies in diﬀerent cancer domains that
reported improvement in various patient outcomes,
attributed to the MDT. The study [10] compared the
outcomes of oesophageal cancer patients in the period after
introduction of specialist team and regular MDT meetings
(1998–2003, n = 67) to those of an earlier period when no
MDT meetings were held (1991–1997, n = 77). Authors
reported lower operative mortality (5.7% versus 26 %,
P = 0.004) and improved 5-year survival (52% versus 10%,
P = 0.0001) in the MDT group. The Scottish study [12]
reviewed outcomes of ovarian cancer patients treated in
1987 (N = 533) and found a survival diﬀerence between
patients managed through a multidisciplinary clinic (MDC)
and those not managed through an MDC (P<0.001). A
before and after study [11] reported a statistically signiﬁcant
but modest improvement of 3.2 months in median survival
of patients with inoperable nonsmall cell lung cancer (3.4
versus 6.6 months, P<0.001). A population based before-
and-after study [13] compared the survival of patients with
invasive cancers, from the Hoag Hospital tumor registry and
reported signiﬁcant improvement in relative 5 year survival
(71% versus 63%, P<0.001) in favour of MDT group. The
Scottish study of elderly people with non-small cell lung
cancer [14] reported improvement in survival following the
introduction of MDT meetings and site specialisation.
The study of patient satisfaction [15] in newly diagnosed
breast cancer patients before and after the establishment
of multidisciplinary breast clinics, reported in favour of
MDT group (P<0.001). In an audit study, Burton et al.
[22] compared preoperative MRI in consultation in MDT
meeting to preoperative MRI without MDT consultation in
rectal cancer patients. They reported that for the incidence
of positive circumferential resection margin (CRM) was
signiﬁcantly higher in the group without MDT consultation
(26% versus 1%).
As t u d y[ 17] found that a clinical trial recruitment rate
in a population of 2,935 colorectal cancer patients diag-
nosed in year 2000, in twelve French administrative districts,
accounting for 15% of the geographical area of France. They
discovered that the patients who were managed through
MDT, the trial recruitment rate was signiﬁcantly higher
(10.3%) compared to that in patients not managed through
MDT (5.1%, P<0.001).
Stephens et al. reported an increase in the number
of patients with oesophageal cancer being staged in the
MDT group (100%) as compared to the historical control
(54%, P = 0.001) [10]. A greater proportion of patients
also received radical radiotherapy in the MDT group (5%)
compared with that of the control (0.5%, P<0.001). In
another study in nonsmall cell lung cancer (NSCLC) patients
[11] there was an increase in the proportion of patients
receiving chemotherapy (23% in the MDT group versus 7%
in control, P<0.001) and the proportion of patients being
staged. A study [16] reported a 30% increase in the annual
lung cancer resection rate (from 14.7 to 19 resections per
year) following the introduction of a telemedicine MDT
meeting. Back et al. [8] retrospectively reviewed the patients
referred to a large radiation therapy centre in SingaporeInternational Journal of Breast Cancer 3
Table 1: Summary of empirical evidence on the eﬀectiveness of cancer MDT meetings.
Outcomes assessed Study E∗ Total cases Cancer type Diﬀerence in MDT meeting arm and control arm
with respect to the outcome
Survival
[7] 2b 88 Lung NSD
[8] 3b 67 Glioma NSD (18.7 versus 11.9 months, P = 0.11)
[9] 4 240 Lung NSD
[10] 4 144 Oesophageal 5 years (52% versus 10%, P<0.001)
[11] 4 243 Lung Median (6.6 months versus 3.2 months)§
[12] 4 533 Ovarian In favour of MDT group§
[13] 4 16035 All cancers 5 years (71% versus 63%, P<0.001)
[14] 4 — Lung 1 year (23.5% versus 18.3%)§
Quality of life [7] 2b 88 Lung NSD
Patient experience [7] 2b 88 Lung Improved in MDT group, P = 0.01
[15] 4 269 Breast Improved in MDT group, P<0.001
Rate of intervention
[11] 4 243 Lung Patients receiving chemo (23% versus 7%)§
[16] 4 112 Lung 30% ↑ in resection in favour of MDT
[8] 3b 67 Glioma Patients having chemo (55% versus 17%)§
[9] 4 240 Lung ↑ in resection (23.4 % versus 12.2%)§
[17] 3b 2935 Colorectal ↑ in trial recruitment (10.3 versus 5.1%)§
Time to intervention
[15] 4 269 Breast Time to treatment (29.6 versus 42.2 days)§
[16] 4 112 Lung NSD
[8] 3b 67 Glioma NSD
Staging accuracy [18] 3b 118 Upper GI MDT improved staging accuracy§
Costs per patients [19] 4 208 Melanoma MDT saved $1600 per patient
Decision quality as
prediction of accuracy [20] 4 50 Lung NSD, Team discussion did not improve the
quality of decision making overall.
Psychological
morbidity of team
members
[21] 5 72 Breast lower prevalence of psychiatric morbidity (15.7%
versus 26.6% P<0.005)
E∗: levels of evidence as deﬁned by Oxford Centre for Evidence-Based Medicine (1a: systematic review of RCTs, 1b: individual RCT (with narrow Conﬁdence
Interval), 1c: all or none, 2a: systematic review of cohort studies, 2b: individual cohort study (including low quality RCT), 2c: “Outcomes” Research, 3a:
systematic review of case-control studies, 3b: individual Case-Control Study, 4: case-series (and poor quality cohort and case-control studies), 5: expert
opinion without explicit critical appraisal, or based on physiology, bench research or “ﬁrst principles”), NSD: no signiﬁcant diﬀerence found in both groups,
§statistically signiﬁcant diﬀerences, and chemo: chemotherapy.
between 2002 and 2006. They reported an increase in the
proportion of patients receiving chemotherapy for high
grade glioma (55% versus 17 %) and also an increase in the
number of patients receiving postoperative imaging within 5
days of surgery in the former group (86% versus 59%) both
in favour of MDT group. In a study comparing the stag-
ing accuracy of individual imaging modalities, endoscopic
ultrasound (EUS), CT scan, and Laparoscopic ultrasound
(LUS) for gastric and oesophageal cancer against that of
collective MDT staging [18] found that collective MDT
staging was more accurate compared with any individual
imaging techniques.
We identiﬁed only one study [19] that evaluated the
cost eﬀectiveness of MDC against a control group. They
looked at cost eﬀectiveness of multidisciplinary melanoma
care at a large academic medical center in the United States
compared to traditional community-based treatment. The
authors concluded that multidisciplinary care would save
$1600 per patient when compared with conventional care.
We did not ﬁnd any studies directly comparing impact
of the MDT meetings on individual team member’s mental
health. A study of breast cancer teams [21] used the
General Health Questionnaire GHQ-12 to assess psychiatric
morbidity, compared it with historic control and concluded
lower prevalence of psychiatric morbidity in breast cancer
MDT members.
4. Evidence Summary
On balance, the number of published studies reporting
positive impact of cancer MDTs is more than the studies that
failed to show beneﬁts. However, the design of almost all
of the studies identiﬁed in this paper was poor. The studies
often used before-and-after designs, which are considered as
weakevidenceforestablishingcausalassociations,becauseof
multiplepotentialconfounders.Theknowledgeaboutcancer
and available diagnostic and treatment options continuously
evolves over time so better outcomes in later periods are4 International Journal of Breast Cancer
more likely. Some of these studies used historical controls
which are well known for introducing signiﬁcant biases
resulting in spurious results. In many of the before-and-after
studies, no adjustment for any confounders were done and
in some [10] a stage drift was found between the groups.
A major problem that we observed in majority of these
studies was multiple concurrent organisational changes in
the intervention group, which might have accounted for the
observed outcome beneﬁts. For example, along with estab-
lishment of MDT meetings, other organisational changes
like centralisation of process and increased caseload [7, 16],
appointment of new specialists [9, 10], and streamlining
of clinical pathways [15] made the interpretation of causal
links between the MDT meetings and observed outcomes
extremelydiﬃcult.Theonlyrandomisedcontroltrialthatwe
found was a pilot RCT with modest sample size (88 patients
in total) and very short follow-up period. The trial was not
powered suﬃciently so making interpretation of the results
very diﬃcult.
Our paper ﬁndings are in line with other previously
published reviews [1, 23–25], all highlighting the paucity
of good-quality evidence to support use of the MDM in
diﬀerent tumour contexts. However, it is important not to
interpret the absence of good-quality evidence as evidence of
ineﬀectiveness. One of the main reasons for the paucity of
the data is the practical diﬃculties in setting up conventional
randomised controlled trials for a complex interventions like
MDTmeetings[26].TherealityisthatcancerMDTmeetings
have already been established as a standard of care in many
healthcare systems making new RCTs in future unlikely.
5. Supporting Overburdened MDT Meetings to
RealiseTheirFullPotential
It seems intuitively obvious that the intervention likes MDT
meetings that are aimed at improving information exchange
and regular communication ﬂow between team members
should beneﬁt the overall care process. This is indirectly
supported by the fact that MDTs are well accepted by
the health community, despite the lack of robust evidence.
As many health care systems have already invested and
committed to the MDT model, the best way forward would
be to focus on improving their conduct to obtain maximum
leverage and to exploit the opportunity created by these
meetings to gather data on patient and process measures to
prospectively assess and document their performance and
eﬀectiveness.
Our paper identiﬁed pragmatic challenges and short-
comings in the current conduct of cancer MDT meetings
which are summarised in Table 2.As u r v e yb yH a w a r de ta l .
of 72 breast multidisciplinary teams in the UK found wide
variation in the treatments received [18]b ys p e c i ﬁ cp a t i e n t
subgroups. Furthermore, there are no formal mechanisms in
place to evaluate compliance with best practice. In another
postal survey of breast MDMs in the UK [27], 29% of
respondents stressed the need for better preparation and
6% noted no recording of decisions made in the MDM,
which raises concern over the decision from the meeting
Table 2: Challenges in realising the full potential of cancer MDT
meeting.
Establishingrobustmechanismsforprospectiveassessmentof
MDT performance
Ensuring MDT recommendations are followed in the practice
Ensuring adherence with standards including evidence-based
guidelines
Establishing reliable interfaces with primary care to ensure
continuity of care
Ensuring active patient participation
Achieving right balance of educational and care delivery
objectives of this forum
Ensuring the consistent collection of crucial data such as
disease staging and outcomes
Limiting exposure of the MDT members to medicolegal
liability
being available for the patient and any members not
present. In the United Kingdom the national cancer peer
review programme, launched in 2001, provides measurable
standards to assess teams’ adherence to the guidance. The
analysis of data collected in the national cancer peer review
programme including over 1000 teams across six cancer
types in England showed that 30% of MDTs did not have
even written protocols for patient management [24]a n d
there was considerable variability in performance.
Some clinicians [28] have raised concerns about the
way cancer MDMs are conducted in UK as frantic business
meetings during which there is little scope for learning
and educational opportunities for the trainees. Furthermore
concerns are raised about their adverse impact on the critical
appraisal skills and independent thought of trainees who
play a passive role in these meetings. Concerns are also
raised about the diminishing role of patients and their
preferences and views may not be fully represented in these
meetings. These is also a danger of MDM recommendations
being conveyed to patients in an authoritarian manner in
which consultations are simply used to obtain consent to
follow MDM recommendations without allowing patients
the ability to fully explore all their available options.
The interfaces between cancer MDTs and primary care
physicians are crucial for the continuity of the care, however
the speciﬁc pathways and methods for handling those
interfaces are not well established [1].
The scale and the extent of the described practical chal-
lenges would vary signiﬁcantly across diﬀerent organisations
and across diﬀerent national healthcare systems. No single
strategy would be suﬃcient to address all the challenges
described earlier and given the complex nature of cancer
MDMs, a multipronged approach would achieve greater
overall beneﬁts.
In the next section, we explore a novel strategy of using
clinical decision support (CDS) technology to address some
of the challenges. We describe one such decision support
system,developedwithanaimtosupportbreastcancerMDT
meetings in the UK hospital, to provide concrete examples of
the capabilities of advanced CDS systems.International Journal of Breast Cancer 5
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Figure 1: Composite screenshot describing some of the functionalities of an example CDS tool developed for breast cancer MDT meeting.
Upperleft:thesummaryscreenforthepatient.Upperright:oneofthemanyprognosticationtoolsavailable,Lowerleft:decisionpanelwhere
system recommendations and eligible clinical trials are highlighted in blue. Lower right: the evidential justiﬁcation for each recommended
option.
6. The Potentialof ClinicalDecision Support
Technology inCancerMDT Meetings
Clinical decision support systems can be deﬁned as “systems
that are designed to be a direct aid to clinical decision-
making in which the characteristics of an individual patient
are matched to a computerised clinical knowledge base,
and patient-speciﬁc assessments or recommendations are
then presented to the clinician(s) and/or the patient for a
decision” [29]. The health information technology such as
electronic patient records (EPRs) could assist in structural
and administrative aspects of cancer MDTs such as prepara-
tion, data collection, presentation, and consistent documen-
tation of decisions. However, advanced CDS systems could
oﬀer services well beyond the use of clinical databases and
EPRs by actively supporting patient-centred, evidence-based
decision-making. One such advanced CDS system called
MATE, Multidisciplinary team Assistant and Treatments
Elector, is being developed for breast MDT meetings and is
being trialed at the London Royal Free hospital. Figure 1 is a
composite image of some of the functionalities of MATE.
An advanced CDS system is able to evaluate all available
patient data in real time, including comorbidities, and oﬀer
prompts, reminders, and suggestions for management in a
transparent way. A CDS system can use national guidelines
and other high-quality evidence to generate patient-speciﬁc
recommendationsandlinkingthemtothesourceofevidence
for transparency.
It is essential to emphasise that CDS systems normally
only suggest optimal management strategy, laying out the
medical logic and relevant supporting documentation and
research; the decision is of course the responsibility of the
members of MDT. Since such systems can compare all MDT
decisions with recommendations, it can also be used to
carry out prospective audit of MDM decisions. Furthermore
CDS technology could also allow clinicians to record their
viewsonguidelinerecommendations,whichcanbecaptured
into a hospital or national database for quality audits and
informing the ongoing guideline development and update
process [30]. Eligibility of patients for recruitment into
ongoing trials could also be screened in real time during
the MDT meetings. The trainee doctors can run cases
through the CDS system and study the recommendations
and evidence against their own decisions.
After the MDM recommendations are discussed with the
patients in results clinic, a CDS system could be accessed by
patients if they wish to revisit the information about their
management pathways. A patient-friendly module of a CDS
system can provide patients with access to and explanations
of clinical recommendations in an appropriate form, thus
helping them to understand the reasons why treatments are
being oﬀered and make better informed decisions. Similarly6 International Journal of Breast Cancer
primary care physicians can access the MDT plans and
recommendations for their patients to provide appropriate
surveillance, survivorship, or palliative care.
MATE provides an example of advanced CDS systems
but it should be borne in mind that there is much work to
be done to establish the best approach in providing CDS
services. Our purpose here is to argue for further research
and debate around this important topic, not to assert the
clinical beneﬁts of using these technologies in the cancer
MDTs.
7. Concluding Remarks
Cancer conferences have come a long way in the last 50 years,
from a forum for presenting interesting cases to a platform
for collaborative day-to-day management of cancer patients.
Given the complex nature of cancer MDT meetings, which
pose signiﬁcant diﬃculties for evaluation, the paucity of
high-qualityevidencefortheireﬀectivenessisnotsurprising.
Signiﬁcant challenges remain in getting maximum leverage
from this important decision-making forum. New research
should be directed to investigate better methods to support
these heavily loaded but key care planning meetings. An
advanced decision support technologies show considerable
promise for supporting clinical, operational, and governance
aspectsofthecancerMDTswithreliability,transparency,and
accountability.
8. Notes
We performed a detailed literature search for published
articles in English for the period 1970 to November 2010.
Data were identiﬁed by searches of MEDLINE, EMBASE,
CINAHL and COCHRANE databases. References of the
retrieved articles were also screened. Combinations of search
terms “multidisciplinary”, “multidisciplinary team”, “mul-
tidisciplinary clinic”, “multidisciplinary cancer conference”,
“multidisciplinary meeting”, “tumour board” and “cancer”
were used. Websites of government agencies and national
health care organisations were also searched for relevant
documents and reports.
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